DUBLIN--(BUSINESS WIRE)--The "Spinal Muscular Atrophy Pipeline Highlights - 2018" report has been added to ResearchAndMarkets.com's offering.
Spinal Muscular Atrophy Pipeline Highlights - 2018, provides the most up-to-date information on key pipeline products in the global Spinal Muscular Atrophy market. It covers emerging therapies for Spinal Muscular Atrophy in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages
The report provides Spinal Muscular Atrophy pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes
The report provides Spinal Muscular Atrophy pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Spinal Muscular Atrophy pipeline products by the company.
Short-term Launch Highlights
Find out which Spinal Muscular Atrophy pipeline products will be launched in the US and Ex-US till 2020.
For more information about this report visit https://www.researchandmarkets.com/research/7cvjgn/spinal_muscular?w=4